ArticleHuman vaccines & immunotherapeutics2025
Seroepidemiological survey of the population 10 years after the implementation of the varicella vaccine 2-dose immunization strategy.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Impact of two-dose varicella vaccination in Guangzhou: An interrupted time-series study.Human vaccines & immunotherapeutics · 2026Article
- Impact of immunization strategies, public health and social measures on the incidence of varicella among children aged 0-14 years in Quzhou City.Human vaccines & immunotherapeutics · 2026Article
- A Cross-Sectional Seroepidemiological Study on Varicella Zoster Virus in Zhejiang, China.Vaccines · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the implementation of a two-dose varicella vaccine (VarV) immunization strategy for over a decade in Quzhou, China, outbreaks of varicella continue to be reported in school settings with high vaccination coverage. This cross-sectional study surveyed healthy individuals aged 3 to 20 years across six districts and counties in Quzhou, China. Serum samples were collected to detect varicella-zoster virus (VZV) IgG antibodies and to evaluate the effectiveness of the two-dose VarV immunization strategy. Among the 1,020 participants, the overall seropositivity rate for VZV IgG was 57.16%, with a median concentration (MC) of 136.46 mIU/mL. Multivariable logistic regression analysis revealed that VZV IgG seropositivity was associated with residence, age group, and VarV immunization history. Single-dose recipients exhibited an antibody peak at 4.34 years, followed by decline to a nadir at 7.95 years and subsequent rebound. In two-dose recipients, antibody levels declined rapidly within the first 1.82 years post-vaccination, followed by a gradual downward trend; nevertheless, levels consistently remained above the protective threshold of 100 mIU/mL. The necessity of booster immunization warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.